Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study reveal encouraging signals in acute MS lesions, suggesting the novel imaging technique could offer a more precise method for measuring myelin loss and repair.
The imaging approach is designed to distinguish demyelinated nerve fibers that may still be viable from those with permanent damage. This distinction is critical for assessing disease progression and the potential for therapeutic intervention. The ability to accurately measure myelin dynamics in living patients could transform how MS is monitored and treated.
These findings are directly relevant to Lucid-MS, the company's investigational compound aimed at inhibiting demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. By combining a more precise imaging tool with a drug candidate designed to address the underlying cause of MS, Quantum BioPharma is positioning itself at the forefront of MS research.
Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions. This milestone is a positive indicator for the ongoing study and the potential clinical utility of both the imaging technique and Lucid-MS.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 19.84% of UWI. The agreement includes royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For more information about Quantum BioPharma, visit the company's newsroom at https://nnw.fm/QNTM.
